Anti-NG2 Purified

*Cattaruzza S, Nicolosi PA, Braghetta P, Pazzaglia L, Benassi MS, Picci P, Lacrima K, Zanocco D, Rizzo E, Stallcup WB, Colombatti A, Perris R: NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion. J Mol Cell Biol. 2013 Jun;5 (3) :176-93., URL: https://pubmed.ncbi.nlm.nih.gov/23559515/, *Girolamo F, Dallatomasina A, Rizzi M, Errede M, Wälchli T, Mucignat MT, Frei K, Roncali L, Perris R, Virgintino D: Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets. PLoS One. 2013 Dec 26;8 (12) :e84883., URL: http://www.ncbi.nlm.nih.gov/pubmed/24386429 Emeren, *Petrovici K, Graf M, Hecht K, Reif S, Pfister K, Schmetzer H: Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics. 2010 Jul-Aug;7 (4) :173-80., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=petrovici+k+graf+m+hecht+k

The mouse monoclonal antibody 7.1 recognizes an extracellular epitope of NG2, the melanoma-associated chondroitin sulfate proteoglycan 4 of Mw approximately 220-300 kDa.